Geron Corp

  • Health Care
  • Biotechnology: Pharmaceutical Preparations
  • www.geron.com
  • Moat Score
  • Safety Score
  • Market Cap $2.70B
  • PE -12
  • Debt $142.35M
  • Cash $116.95M
  • EV $2.72B
  • FCF -$208.59M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$219.55M
EBIT-$227.37M
ROE-72%
ROA-51%
FCF-$208.59M
Equity$306.70M
Growth Stability1
PE-12.28
PB8.79
P/FCF-12.93
P/S1.96K
Price/Cash0.04
Debt/Equity0.46
Debt/FCF-0.68
Net Margins-10K%
Op. Margins-17K%
Sales Growth YoY3K%
Sales Growth QoQ190%
Sales CAGR-30%
Equity CAGR7%
Earnings Growth YoY37%
Earnings Growth QoQ22%
Sales CAGR 5Y8%
Equity CAGR 5Y13%
Earnings CAGR 3Y-23%
Sales CAGR 3Y-23%
Equity CAGR 3Y55%
Market Cap$2.70B
Revenue$1.37M
Assets$449.40M
Total Debt$142.35M
Cash$116.95M
Shares Outstanding628.7M
EV2.72B
Moat Score1%
Safety Score64%
Working Capital269.77M
Current Ratio3.61
Shares Growth 3y32%
Equity Growth QoQ-11%
Equity Growth YoY3%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.

SEC Filings

Direct access to Geron Corp (GERN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Geron Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Geron Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Geron Corp Discounted Cash Flow

Fully customizable DCF calculator online for Geron Corp.

= -$2.1B
012345678910TV
fcf-$209M-$209M-$209M-$209M-$209M-$209M-$209M-$209M-$209M-$209M-$209M-$2.1B
DCF-$190M-$172M-$157M-$142M-$130M-$118M-$107M-$97M-$88M-$80M-$804M
Value-$2.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-3K%0%-479%-3K%-3K%-15K%-30K%-8K%-24K%-78K%-10K%
ROA--0%-24%-27%-17%-44%-28%-50%-73%-49%-51%
ROE-0%-24%-27%-15%-51%-36%-92%-177%-74%-72%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-------0.36-0.52-0.4-0.49-0.68
Debt over Equity------0.110.390.640.330.46
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-3K%-83%-83%0%-57%-45%451%-57%-60%8%
Earnings YoY growth--100%-64K%-5%-3%154%10%54%22%30%-
Equity YoY growth-9%-14%-15%71%-24%56%-40%-37%210%13%
FCF YoY growth--363%-24%--110%52%43%33%32%-